CG Oncology Inc
CGON
ISIN US1569441009 / Valor 131996952
CG Oncology Inc
UMushroom community rating:
About company
CG Oncology Inc. is a late-stage clinical biopharmaceutical company dedicated to the development and commercialization of oncolytic immunotherapies for bladder cancer. The company's primary investigational drug, cretostimogene, is designed to treat BCG-unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC). Although not yet approved by any regulatory agency, cretostimogene has demonstrated clinical benefits and has been generally well-tolerated in clinical trials, both as a monotherapy and in combination with other treatments. CG Oncology aims to provide innovative therapeutic options that enhance the quality of life for patients with urologic cancers.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
2180 M
Market cap (USD)
244,561
Daily traded volume (Shares)
33.15 / 31.4
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
